Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05675787
Other study ID # 2022PHB416
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 6, 2023
Est. completion date October 31, 2025

Study information

Verified date May 2023
Source Peking University People's Hospital
Contact WANG JIANLIU, PhD/MD
Phone +861088324383
Email wangjianliu1203@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.


Description:

After diagnosed of AEH or EEC by hysteroscopy, patients meet the study criteria will be enrolled. The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue was detected by Raman scattering instrument. And Age, height, weight, waistline, blood pressure, basic history of infertility and family cancer will be collected. Blood tests, including fasting blood glucose (FBG), fasting insulin (FINS), blood lipids, sex hormone levels, anti-müllerian hormone (AMH) and renal/liver function tests will be performed before treatment to evacuate their basic conditions. Each subject will receive body fat testing by Inbody 770. Patients will receive MPA (Medroxyprogesterone acetate) 250-500 mg by mouth daily plus atorvastatin 20mg by mouth daily for at least 3 months. Then hysteroscopy will be used to evaluate the endometrial condition every 3 months, and intra-operative findings will be recorded. Complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to hyperplasia with or without atypic; stable disease (SD) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of higher pathological progression, or myometrial invasion, or extra-uterine metastasis. Continuous therapies will be needed in PR. Patients with PD will be recommended for hysterectomy. For patients remained SD after 9 months of treatment but refused hysterectomy, a multiple disciplinary discussion would be held for individual case, and alternative treatment would be given. Three months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for at least 1 year.


Recruitment information / eligibility

Status Recruiting
Enrollment 82
Est. completion date October 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 17 Years to 45 Years
Eligibility Inclusion Criteria: - Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove AEH or well-differentiated EEC G1 without myometrial invasion: 1. Untreated patients; 2. Patients with persistent lesions after one course (12 weeks) of progesterone therapy; 3. Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy; - No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound - Have a desire for remaining reproductive function or uterus - Good compliance with adjunctive treatment and follow-up Exclusion Criteria: - Hypersensitivity or contradiction for using MPA or atorvastatin - Pregnancy or potential pregnancy - Confirmed diagnosis of any cancer in reproductive system - Already diagnosed with hyperlipidemia and using lipid-lowering drugs - Acute liver disease or liver tumor (benign or malignant) or renal dysfunction - Acute severe disease such as stroke or heart infarction or a history of thrombosis disease - With other factors of reproductive dysfunction; - Strong request for uterine removal or other conservative treatment - Smoker (>15 cigarettes a day) - Drinker (>20 grams a day)

Study Design


Intervention

Drug:
Medroxyprogesterone acetate + Atorvastatin
MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,

Locations

Country Name City State
China Wang Jianliu Peking Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological cumulative complete response rate; 3 to 4 months: From date of initial therapy until the date of CR or date of hysterectomy, assessed up to 4 months
Secondary Pathological cumulative complete response rate; From 6 to 8 months; From date of initial therapy until the date of CR or date of hysterectomy, assessed up to 8 months
Secondary The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion assessed up to 4 months
Secondary Overall complete response rate Pathological response duration up to 2 years
Secondary Pathological response rate classified by different blood lipid level Pathological response rate classified by different blood lipid level up to 2 years;
Secondary Relapse rate Relapse rate up to 15 months after the end of treatment
Secondary Pregnancy rate Pregnancy rate up to 15 months after the end of treatment
Secondary Toxic Side Effect Toxicity evaluation according to CTCAE 5.0 version. up to 3 months after the end of treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02397083 - Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Phase 2
Recruiting NCT05647109 - Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
Completed NCT04491682 - Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia Phase 2/Phase 3
Active, not recruiting NCT00788671 - Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer Phase 2
Completed NCT04385667 - LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia Phase 2/Phase 3
Withdrawn NCT01943058 - Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer Phase 2
Withdrawn NCT04683237 - Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Completed NCT00483327 - Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate Phase 2
Recruiting NCT05316493 - Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Completed NCT03241888 - Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia Phase 2/Phase 3
Recruiting NCT06390904 - GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients Phase 2/Phase 3
Recruiting NCT05316935 - GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients Phase 2/Phase 3
Recruiting NCT06379113 - GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients Phase 2/Phase 3
Recruiting NCT05172999 - Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Active, not recruiting NCT03671811 - Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy Phase 2
Completed NCT00490087 - Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Phase 3
Terminated NCT04607252 - Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia Phase 2/Phase 3
Recruiting NCT05051722 - Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Active, not recruiting NCT00892866 - CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells N/A
Recruiting NCT03463252 - Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Phase 2/Phase 3